By FieldPulse Editorial · March 26, 2026
Tags: Policy, Compliance, Drug Pricing
Senate Republicans have launched a formal investigation into how mifepristone is marketed and distributed, while congressional scrutiny of the 340B drug discount program intensifies. Both carry real implications for reps in reproductive health and hospital accounts.
Two parallel legislative developments reported on March 26 are drawing attention from pharma industry observers: Senate Republicans have opened a formal investigation into the marketing and distribution practices of mifepristone manufacturers, and congressional pressure on the 340B drug discount program is continuing to build. The mifepristone investigation adds a new layer of congressional scrutiny to a drug that has been at the center of legal and political battles since the Supreme Court's 2022 Dobbs decision. Mifepristone, approved by the FDA for medication abortion and also used in miscar